Please wait...


Generic Name: niraparib (nye RAP a rib)
Brand Names: Zejula
Zejula (niraparib) is used to treat recurrent ovarian, fallopian tube, or peritoneal cancer. Includes Zejula side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Zejula

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Zejula (niraparib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Zejula is used as a maintenance treatment to keep certain types of cancer from coming back. This includes ovarian cancer, fallopian tube cancer, or peritoneal cancer (the peritoneum is the membrane that lines the inside of your abdomen and covers some of your internal organs). Zejula is used after you have received platinum-based chemotherapy (cisplatin, oxaliplatin, carboplatin, or similar) and your cancer has responded to that medicine. Learn more

Zejula Side Effects

Zejula Side Effects

Note: This document contains side effect information about niraparib. Some of the dosage forms listed on this page may not apply to the brand name Zejula.

In Summary

Common side effects of Zejula include: anemia, asthenia, constipation, cough, decreased hemoglobin, decreased neutrophils, decreased platelet count, decreased white blood cell count, dizziness, dyspnea, fatigue, headache, hypertension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, insomnia, mucositis, nasopharyngitis, nausea, neutropenia, palpitations, skin rash, stomatitis, thrombocytopenia, vomiting, decreased appetite, dysgeusia, and xerostomia. Other side effects include: hypertensive crisis. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to niraparib: oral capsule

Along with its needed effects, niraparib (the active ingredient contained in Zejula) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking niraparib:

More common

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • blurred vision
  • chills
  • cough
  • dizziness
  • fast, irregular, pounding, or racing heartbeat or pulse
  • fever
  • headache
  • lower back or side pain
  • nervousness
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • pounding in the ears
  • slow or fast heartbeat
  • sore throat
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Less common

  • Chest pain
  • swollen glands

Some side effects of niraparib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Acid or sour stomach
  • back pain
  • belching
  • bladder pain
  • bloody or cloudy urine
  • change in taste
  • cracked lips
  • decreased appetite
  • diarrhea
  • difficulty having a bowel movement (stool)
  • difficulty with swallowing
  • dry mouth
  • fear or nervousness
  • frequent urge to urinate
  • heartburn
  • indigestion
  • lack or loss of strength
  • loss of taste
  • lower back or side pain
  • nausea
  • stomach discomfort, upset, or pain
  • trouble sleeping
  • vomiting

For Healthcare Professionals

Applies to niraparib: oral capsule


The most commonly reported adverse reactions (incidence 20% or greater) were

decreased hemoglobin (85%), decreased platelet count (82%), nausea (74%), decreased white blood cell count (66%), thrombocytopenia (61%), fatigue/asthenia (57%), decreased absolute neutrophil count (53%), anemia (50%), constipation (40%), increased AST (36%), vomiting (34%), abdominal pain/distention (33%), neutropenia (30%), increased ALT (28%), insomnia (27%), headache (26%), decreased appetite (25%), nasopharyngitis (23%), rash (21%), diarrhea (20%), dyspnea (20%), hypertension (20%), and mucositis/stomatitis (20%).


Very common (10% or more): Decreased hemoglobin (85%), decreased platelet count (82%), decreased white blood cell count (66%), thrombocytopenia (61%), decreased absolute neutrophil count (53%), anemia (50%), neutropenia (30%), leukopenia (17%)


Very common (10% or more): Nausea (74%), constipation (40%), vomiting (34%), abdominal pain/distention (33%), diarrhea (20%), mucositis/stomatitis (20%), dyspepsia (18%), dry mouth (10%)


Very common (10% or more): Fatigue/asthenia (57%)

Common (1% to 10%): Peripheral edema


Very common (10% or more): Increased AST (36%), Increased ALT (28%), AST/ALT elevation (10%)

Common (1% to 10%): Increased gamma-glutamyl transferase, increased blood alkaline phosphatase


Very common (10% or more): Insomnia (27%), anxiety (11%)

Common (1% to 10%): Depression

Nervous system

Very common (10% or more): Headache (26%), dizziness (18%), dysgeusia (10%)


Very common (10% or more): Decreased appetite (25%)

Common (1% to 10%): Hypokalemia, decreased weight


Very common (10% or more): Nasopharyngitis (23%), dyspnea (20%), cough (16%)

Common (1% to 10%): Bronchitis, epistaxis


Very common (10% or more): Rash (21%)


Very common (10% or more): Hypertension (20%), palpitations (10%)

Common (1% to 10%): Tachycardia

Frequency not reported: Hypertensive crisis


Very common (10% or more): Myalgia (19%), back pain (18%), arthralgia (13%)


Very common (10% or more): Urinary tract infection (13%)


Common (1% to 10%): Conjunctivitis


Common (1% to 10%): Increased blood creatinine


Uncommon (0.1% to 1%): Myelodysplastic Syndrome/Acute Myeloid Leukemia

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Zejula